Biotech Values

[DonShimoda]

...now that money has little short term catalyst to keep holding...

Based on the ASCO data, I think it's highly likely that the next catalyst will be FDA approval of the AP534 registration trial. After that we may get the P2 endometrial results and possibly an announcement from MRK about their plans for Rida/DALO in breast cancer (impressive P1 results in luminal b were released at ASCO). So, I do think they'll be some opportunities for the stock to move higher into the rida final analysis but I don't see it making new highs until the SUCCEED trial results are known.